Trevi Therapeutics, Inc. (TRVI)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Trevi Therapeutics, Inc. (TRVI)
Go deeper and ask any question about TRVI
Company Performance
Current Price
as of Sep 13, 2024$3.37
P/E Ratio
N/A
Market Cap
$244.63M
Description
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Metrics
Overview
- HQNew Haven, CT
- SectorHealth Technology
- IndustryBiotechnology
- TickerTRVI
- Price$3.37+2.12%
Trading Information
- Market Cap$244.63M
- Float64.08%
- Average Daily Volume (1m)188,129
- Average Daily Volume (3m)222,714
- EPS-$0.39
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$12.35M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$13.25M
- EV$232.80M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Earnings Calls
Factset Street Account